Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2162-2165

  Stoddart, Cheryl A ^a   Nault, Geneviève ^b,c   Galkina, Sofiya A ^a   Bousquet Gagnon, Nathalie ^b,d   Bridon, Dominique ^b,e   Quraishi, Omar ^b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c Biomod Concepts Inc   (Canada)

^d UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^e Optivia Biotechnology Inc   (United States)

^f ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C34 PEPTIDE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PC 1505; SERUM ALBUMIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE;

ANIMALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; GENES, MHC CLASS I; HIV CORE PROTEIN P24; HIV FUSION INHIBITORS; HIV INFECTIONS; MICE; MICE, SCID; ORGANOPHOSPHORUS COMPOUNDS; PEPTIDES; RNA, VIRAL; THYMOCYTES;

EID: 84858626049     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05015-11     Document Type: Article

References (17)

1. Denton PW, et al. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5:e16.
2. Denton PW, et al. 2010. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5:e8829.
3. Gilden D. 1998. T-20 and adefovir for salvage therapy - expect no miracles. GMHC Treat. Issues 12:6-7.
4. Grant RM, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
5. Hamburger AE, Kim S, Welch BD, Kay MS. 2005. Steric accessibility of the HIV-1 gp41 N-trimer region. J. Biol. Chem. 280:12567-12572.
6. Jette L, et al. 2005. Human growth hormone-releasing factor (hGRF)1- 29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146:3052-3058. (Pubitemid 41002813)
7. Leger R, et al. 2004. Kringle 5 peptide-albumin conjugates with antimigratory activity. Bioorg. Med. Chem. Lett. 14:841-845. (Pubitemid 38167599)
8. Leger R, et al. 2003. Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates. Bioorg. Med. Chem. Lett. 13:3571-3575. (Pubitemid 37141432)
9. Leger R, et al. 2004. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg. Med. Chem. Lett. 14: 4395-4398. (Pubitemid 39043956)
10. Liu S, et al. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280:11259-11273. (Pubitemid 40418432)
11. Manfredi R, Sabbatani S. 2006. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr. Med. Chem. 13:2369-2384. (Pubitemid 44184643)
12. Rabin L, et al. 1996. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob. Agents Chemother. 40:755-762. (Pubitemid 26071545)
13. Stoddart CA, et al. 2007. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2:e655.
14. Stoddart CA, et al. 2007. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2:e1251.
15. Stoddart CA, et al. 2000. Antiviral activity of 2′-deoxy-3′- oxa-4′- thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob. Agents Chemother. 44:783-786. (Pubitemid 30117983)
16. Stoddart CA, et al. 2008. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283:34045-34052.
17. Thibaudeau K, et al. 2005. Synthesis and evaluation of insulin-human serum albumin conjugates. Bioconjug. Chem. 16:1000-1008. (Pubitemid 41026186)